Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium

Clinical and Experimental Rheumatology

Volumn 20, Issue 3, 2002, Pages 351-358

  Choy, Ernerst H S ^a   Scott, D L ^a   Kingsley, G H ^a   Williams, P ^a   Wojtulewski, J ^a   Papasavvas, G ^a   Henderson, E ^a   Macfarlane, D ^a   Erhardt, C ^a   Young, A ^a   Plant, M J ^a   Panayi, G S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

DMARDs; Early treatment; Randomised controlled trial; Rheumatoid arthritis; Sulphasalazine; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; ANEMIA; ARTHRITIS; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HERPES ZOSTER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEROLOGY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0036558915     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Inter-relationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants [see comments]
2. Disease activity and joint damage progression in early rheumatoid arthritis: Relation to IgG, IgA, and IgM rheumatoid factor
3. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis
4. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients
5. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive?
6. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
7. Development and validation of response criteria in rheumatoid arthritis: Steps towards an international consensus on prognostic markers
8. Disease activity in rheumatoid arthritis: Preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research
9. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities
10. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial
11. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
12. Sulphasalazine in rheumatoid arthritis: A double blind comparison of sulphasalazine with placebo and sodium aurothiomalate
13. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
14. A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis
15. A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis
16. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomised double blind trial
17. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
18. Sulfasalazine in early rheumatoid arthritis
19. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: Evidence of an earlier effect of sulphasalazine
20. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
21. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial
22. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
23. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
24. Sulphasalazine in the treatment of rheumatoid arthritis
25. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine
26. Response to sulfasalazine in rheumatoid arthritis: Life table analysis of a 5-year followup
27. Sulfasalazine treatment for rheumatoid arthritis: A metaanalysis of 1 5 randomized trials
28. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxchloroquine, or a combination of all three medications
29. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
30. Challenging the therapeutic pyramid: A new look at treatment strategies for rheumatoid arthritis
31. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
32. Prognostic criteria in rheumatoid arthritis: Can we predict which patients will require specific anti-rheumatoid treatment?
33. Sulphasalazine in rheumatoid arthritis: A double blind comparison of sulphasalazine with placebo and sodium aurothiomalate
34. Placebo-controlled studies in rheumatoid arthritis: Ethical issues
35. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group